



Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification

Rie Jo · Hirotaka Shibata · Isao Kurihara · Kenichi Yokota · Sakiko Kobayashi · Ayano Murai-Takeda · Yuko Mitsuishi · Takeshi Hayashi · Toshifumi Nakamura · Hiroshi Itoh

Published online: 13 January 2023

© The Author(s), under exclusive licence to The Japanese Society of Hypertension 2023

Correction to: *Hypertension Research* (2022) 46:19–31
<https://doi.org/10.1038/s41440-022-01036-6>

The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 µg/g.

There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E.

The original article has been corrected.